Who
Richard Ian Griffiths
10% owner
Company insider
Files Form 4 as: 10% owner, Silence Therapeutics.
In numbers
- Trades disclosed
- 103
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 8 Jan 2025
- Last trade
- 10 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —2,792,826 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —60,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —100,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —100,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —50,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —2,792,826 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —100,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —50,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —3,500 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —800,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —382,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —470,820 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —605,174 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —120,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —60,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —100,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —3,500 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —800,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —382,000 | filing |
| 10 Aug 2026filed 13 Aug 2026 | SLN Silence Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | —470,820 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.